Back to top
more

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$1.93 USD

1.93
16,438,753

+0.16 (9.04%)

Updated May 13, 2024 04:00 PM ET

After-Market: $1.93 0.00 (0.00%) 7:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock

Pacific Biosciences (PACB) needs investors to pay close attention to the stock based on moves in the options market lately.

    What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?

    Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.

      Pacific Biosciences Hurt by Competition in Niche Markets

      Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.

        Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated

        Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.

          Pacific Biosciences, Bluebee Team Up for De Novo Sequencing

          With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.

            Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss

            Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.

              Pacific Biosciences (PACB) Prices Offering of Common Stock

              Pacific Biosciences of California, Inc. (PACB) recently announced that it has priced its underwritten public offering of 15.4 million shares of its common stock.

                Pacific Biosciences (PACB) Q1 Loss Wider than Estimated

                Pacific Biosciences of California Inc. (PACB) reported a loss of 26 cents per share in the first quarter of 2017. The figure is 3 cents wider than the Zacks Consensus Estimate.

                  Pacific Biosciences (PACB): What Awaits in Q1 Earnings?

                  Pacific Biosciences of California Inc. (PACB) is scheduled to report first-quarter 2017 results on Apr 20.

                    Pacific Biosciences (PACB) Up 5.5% Since Earnings Report: Can It Continue?

                    Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Pacific Biosciences (PACB) Q4 Loss Narrower than Estimated

                      Pacific Biosciences of California Inc. (PACB), a pioneer in the field of single molecule long resequencing, reported loss of 21 cents per share in the fourth quarter of 2016, 2 cents narrower than the Zacks Consensus Estimate.

                        Pacific Biosciences (PACB): What Awaits in Q4 Earnings?

                        Pacific Biosciences of California Inc. (PACB) is scheduled to report fourth-quarter 2016 results on Feb 1, 2017.

                          Pacific Biosciences (PACB) to Sell 10 PacBio Sequel Systems

                          Pacific Biosciences of California, Inc. (PACB), announced that it will sell 10 PacBio Sequel Systems to Novogene Bioinformatics Technology Company, Ltd.

                            Pacific Biosciences Terminates SMRT Agreement with Roche

                            Pacific Biosciences of California, Inc. (PACB), announced that F. Hoffman-La Roche Ltd has chosen to terminate a preexisting development, commercialization and license agreement.